249 related articles for article (PubMed ID: 35846951)
1. Experimental Animal Models for Moyamoya Disease: A Species-Oriented Scoping Review.
Cao L; Dong Y; Sun K; Li D; Wang H; Li H; Yang B
Front Surg; 2022; 9():929871. PubMed ID: 35846951
[TBL] [Abstract][Full Text] [Related]
2. Experimental animal models for moyamoya disease and treatment: a pathogenesis-oriented scoping review.
Rallo MS; Akel O; Gurram A; Sun H
Neurosurg Focus; 2021 Sep; 51(3):E5. PubMed ID: 34469865
[TBL] [Abstract][Full Text] [Related]
3. The Pathophysiology of Moyamoya Disease: An Update.
Bang OY; Fujimura M; Kim SK
J Stroke; 2016 Jan; 18(1):12-20. PubMed ID: 26846756
[TBL] [Abstract][Full Text] [Related]
4. Moyamoya Disease and Spectrums of RNF213 Vasculopathy.
Bang OY; Chung JW; Kim DH; Won HH; Yeon JY; Ki CS; Shin HJ; Kim JS; Hong SC; Kim DK; Koizumi A
Transl Stroke Res; 2020 Aug; 11(4):580-589. PubMed ID: 31650369
[TBL] [Abstract][Full Text] [Related]
5. Infarct Pattern and Collateral Status in Adult Moyamoya Disease: A Multimodal Magnetic Resonance Imaging Study.
Kim DY; Son JP; Yeon JY; Kim GM; Kim JS; Hong SC; Bang OY
Stroke; 2017 Jan; 48(1):111-116. PubMed ID: 27909201
[TBL] [Abstract][Full Text] [Related]
6. Moyamoya disease: a summary.
Burke GM; Burke AM; Sherma AK; Hurley MC; Batjer HH; Bendok BR
Neurosurg Focus; 2009 Apr; 26(4):E11. PubMed ID: 19335127
[TBL] [Abstract][Full Text] [Related]
7. Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review.
Liao X; Deng J; Dai W; Zhang T; Yan J
Environ Health Prev Med; 2017 Nov; 22(1):75. PubMed ID: 29165161
[TBL] [Abstract][Full Text] [Related]
8. The Genetic Basis of Moyamoya Disease.
Mertens R; Graupera M; Gerhardt H; Bersano A; Tournier-Lasserve E; Mensah MA; Mundlos S; Vajkoczy P
Transl Stroke Res; 2022 Feb; 13(1):25-45. PubMed ID: 34529262
[TBL] [Abstract][Full Text] [Related]
9. Moyamoya Disease.
Fujimura M; Bang OY; Kim JS
Front Neurol Neurosci; 2016; 40():204-220. PubMed ID: 27960175
[TBL] [Abstract][Full Text] [Related]
10. Current Understanding of Moyamoya Disease (MMD) and Associated Neuropsychiatric Outcomes.
Antonov A; Terraciano A; Essibayi MA; Javed K; Altschul DJ
Neuropsychiatr Dis Treat; 2023; 19():2673-2680. PubMed ID: 38090021
[TBL] [Abstract][Full Text] [Related]
11. Moyamoya disease: a case of vanishing cerebral vessels.
Thanavaro JL; Nemani N; Price HI
J Am Assoc Nurse Pract; 2013 Apr; 25(4):173-179. PubMed ID: 24218234
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Basal Collaterals in Moyamoya Disease: Clinical and Genetic Factors.
Chung JW; Kim SJ; Bang OY; Kim KH; Ki CS; Jeon P; Yeon JY; Kim JS; Hong SC; Shin HJ
Eur Neurol; 2016; 75(3-4):178-85. PubMed ID: 27046023
[TBL] [Abstract][Full Text] [Related]
13. Experimental animal models for the study of moyamoya disease.
Letchuman V; Ampie L; Mastorakos P; Raper DMS; Kellogg RT; Park MS
Neurosurg Focus; 2021 Sep; 51(3):E4. PubMed ID: 34469866
[TBL] [Abstract][Full Text] [Related]
14. Failures in Revascularization for Pediatric Moyamoya Disease and Syndrome: A Scoping Review.
Shlobin NA; Frankel HG; Lam S
World Neurosurg; 2021 May; 149():204-214.e1. PubMed ID: 33618047
[TBL] [Abstract][Full Text] [Related]
15. Multiomics and blood-based biomarkers of moyamoya disease: protocol of Moyamoya Omics Atlas (MOYAOMICS).
Ge P; Yin Z; Tao C; Zeng C; Yu X; Lei S; Li J; Zhai Y; Ma L; He Q; Liu C; Liu W; Zhang B; Zheng Z; Mou S; Zhao Z; Wang S; Sun W; Guo M; Zheng S; Zhang J; Deng X; Liu X; Ye X; Zhang Q; Wang R; Zhang Y; Zhang S; Wang C; Yang Z; Zhang N; Wu M; Sun J; Zhou Y; Shi Z; Ma Y; Zhou J; Yu S; Li J; Lu J; Gao F; Wang W; Chen Y; Zhu X; Zhang D; Zhao J
Chin Neurosurg J; 2024 Feb; 10(1):5. PubMed ID: 38326922
[TBL] [Abstract][Full Text] [Related]
16. Flow-augmentation bypass for moyamoya disease.
Fujimura M; Tominaga T
J Neurosurg Sci; 2021 Jun; 65(3):277-286. PubMed ID: 33245218
[TBL] [Abstract][Full Text] [Related]
17. Anesthetic challenges in pediatric moyamoya disease: A report of two cases.
Bhatnagar V; Kulkarni SN; Sharma A; Dolla SB
Brain Circ; 2020; 6(1):47-51. PubMed ID: 32166200
[TBL] [Abstract][Full Text] [Related]
18. Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease.
Kanoke A; Fujimura M; Niizuma K; Fujimura T; Kakizaki A; Ito A; Sakata H; Sato-Maeda M; Kure S; Tominaga T
Brain Res; 2016 Jul; 1642():1-9. PubMed ID: 26972532
[TBL] [Abstract][Full Text] [Related]
19. Abnormal Embryonic Development of Cerebral Arteries as a Potential Cause of Moyamoya Disease.
Tan C; Niu H; Duan R; Shi G; Zhao Y; Chen X; Ye X; Wang R
World Neurosurg; 2019 Sep; 129():e224-e232. PubMed ID: 31125778
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Profiling of Intracranial Arteries in Adult Patients With Moyamoya Disease Reveals Novel Insights Into Its Pathogenesis.
Xu S; Wei W; Zhang F; Chen T; Dong L; Shi J; Wu X; Zhang T; Li Z; Zhang J; Li X; Chen J
Front Mol Neurosci; 2022; 15():881954. PubMed ID: 35711733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
